Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
CALGARY, Alberta, Oct. 16, 2017 -- Zenith Capital Corp. (“Zenith” or the “Company”) today announces its participation in the upcoming BIO Investor Forum in San Francisco, CA. Mr. Donald J. McCaffrey, President and Chief Executive Officer, will provide a corporate update and overview of recent activities at the conference.
Presentation & Webcast Details:
Date: Tuesday, October 17th
Time: 11:15 am PT
Duration: ~15 minutes
Location: Elizabethan D Room at the Westin St. Francis
Webcast Link: Click hear to launch the webcast viewer
The presentation will be available on the Company’s website immediately prior to the start of the event. Click on this LINK to go directly to the appropriate page on the Company’s website. An archived replay of the webcast will also be available on the Company website by clicking on this LINK.
About Zenith
Zenith Capital Corp. is a biotechnology investment company. Zenith Epigenetics Ltd., a wholly-owned subsidiary of Zenith Capital Corp., is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics. Zenith Epigenetics Ltd.’s bromodomain (BET) inhibitors are being advanced in several oncology indications and have the potential to impact multiple additional diseases as well. The lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (“mCRPC”).
For further information, please contact:
Clayton Paradis
Zenith Capital Corp.
Phone: 587-390-7865
Email: [email protected]
Website: www.zenithepigenetics.com
